Visual loss

Displaying 6 studies

  • Functional Assessment of Ultra-Low Vision Rochester, MN

    The purpose of this study is to assess the feasibility and validity of novel online tests of visual functioning that can be administered without the need for an in-person lab visit and then determine the degree to which those tests are predictive of visual functioning in daily life; specifically, for activities of daily living (ADL), in people across the spectrum of mild to severe low vision.

  • New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System Rochester, MN

    This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.

  • Outcomes of Perioperative Vision Loss Rochester, MN

    The goal of this study is to update the incidence of perioperative vision loss from ischemic optic neuropathy, retinal vein or artery occlusion, and cortical blindness from all non-ocular general anesthesia surgery, including robotic surgery, that has been performed at Mayo Clinic from 2003-2012. The study will also aim to determine the visual acuity outcomes following perioperative vision loss.

  • A Study to Evaluate the Effectiveness and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema Jacksonville, FL

    The purpose of this study is to evaluate the effectiveness and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).

  • Fenofibrate for Prevention of DR Worsening Rochester, MN

    The purpose of this study is to evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening or center-involved diabetic macular edema (CI-DME) with vision loss through 4 years of follow-up in participants with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline.

  • Developing Criteria for Treatment of Neurofibromatosis Type 1 Associated Optic Pathway Glioma Rochester, MN

    The purpose of this research study is to understand the natural history of vision in patients with OPG and determine if there are factors (e.g. age at diagnosis, male/female, tumor location, features of the MRI exam, etc) that predict future vision loss or change in tumor size.

    Another purpose of the study is to collect and store blood and tissue samples to use for future research to evaluate if there are certain variations in DNA, RNA, or proteins that predict the likelihood of an OPG to grow or cause vision loss.

.

Mayo Clinic Footer